01 March 2017 by Nair Yukie Maeda

Improved platelet aggregation following administration of phosphodiesterase-5 inhibitors in patients with Eisenmenger syndrome


Platelet aggregation (PA) has been shown to be decreased in pulmonary arterial hypertension (PAH) associated with the Eisenmenger syndrome (PAH-ES). Platelets probably become “exhausted” following chronic endogenous activation, with decreased response when aggregation is analyzed in vitro.


We analyzed platelet aggregation before and during administration of phosphodiesterase-5 inhibitors (PDE-5is, sildenafil and tadalafil) in PAH-ES adults.


Twenty-three naïve patients were aged 25 (18-40) years (median and interquartile range). Sildenafil (20mg t.i.d., n=11) or tadalafil (single daily dose of 40mg, n=12) were administered orally, and laboratory data were obtained at baseline, 3 and 6 months of treatment. Whole blood ADP-induced PA was analyzed by the impedance method.


At baseline, patients had decreased oxygen saturation (O2 sat. 87% ([80-92]%), increased hematocrit (Htc 54% [49-61%]) and platelet count of 210 (180-261) x 109 pl/L. Compared to normals, PA was 47% decreased and directly influenced by platelet count (R2= 0.54, p<0.001). Treatment with PDE-5is was followed by decrease in Htc (p<0.001), although resting O2 sat., did not change.  There was a mild decrease in platelet count (p=0.093), particularly in the sildenafil group. Compared to baseline, PA improved (p=0.048) with further increase when it was normalized by platelet count (p=0.014). There were no differences between treatment groups.


In PAH-ES patients, in vitro PA was improved by treatment with PDE-5is. We speculate that this might be due to improvement of chronic endogenous platelet activation.

About the author

profile picture of Nair Yukie Maeda

Key Contributors

Nair Yukie Maeda1, Mariana Meira Clavé2, Sergio Paulo Bydlowski3, Antonio Augusto Lopes2. 1Pro-Sangue Foundation, São Paulo, Brazil, 2 Heart Institute, 3 LIM-31, University of São Paulo School of Medicine, São Paulo, Brazil

Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI